Related Experiment Videos
Human rabies immunoprophylaxis using HDC (MRC-5) vaccine
Developments in Biological Standardization
|January 1, 1978
Summary
This study shows that a beta-propiolactone inactivated rabies vaccine (hdc) mrc-5 is safe and effective for rabies prevention. Prophylactic vaccination in high-risk individuals resulted in high antibody titers and 100% seroconversion with no major side effects.
Area of Science:
- Virology
- Immunology
- Public Health
Background:
- Rabies remains a significant global health threat, necessitating effective prophylactic measures.
- High-risk populations require robust vaccination strategies to prevent rabies exposure.
Purpose of the Study:
- To evaluate the immunogenicity and safety of a beta-propiolactone inactivated rabies vaccine (hdc) mrc-5 in a field trial.
- To assess neutralizing antibody titers following a prophylactic vaccination schedule.
Main Methods:
- A field trial involving 181 high-risk individuals (ages 2-71) receiving 1 ml of vaccine intramuscularly on days 0, 7, and 21.
- Serum samples collected on days 0, 7, 21, and 35.
- Neutralizing antibody titers determined using the rapid fluorescent focus inhibition test.
Main Results:
- Measurable rabies virus neutralizing antibody titers were detected in nearly all participants by day 7.
- 100% seroconversion was achieved by day 21, with a mean titer of 1:1000 (8.3 IU/ml).
- By day 35, the mean antibody titer increased to 1:2400 (20 IU/ml).
Conclusions:
- The beta-propiolactone inactivated rabies vaccine (hdc) mrc-5 demonstrated excellent immunogenicity in high-risk individuals.
- The prophylactic vaccination regimen was well-tolerated, with no major observed side effects.
- This vaccine represents a safe and effective option for rabies pre-exposure prophylaxis.